Drugs / Lung cancer-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03356808 | Jun 2026 → Dec 2029 expected | lung cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lung cancer-specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03356808 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor modified-T cells (CAR T)” NCT03356808 ↗ |
| Route | Intravenous | “given back to the participant by intravenous infusion” NCT03356808 ↗ |